Signal2026-07-09
ClinicalTrials.gov

[PHASE1] A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC

Part of

Cancer Immunotherapy And Combination Strategies

Open primary sourceRead on Substack